MedPath

Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

23

Active:4
Completed:1

Trial Phases

4 Phases

Phase 1:10
Phase 2:4
Phase 3:8
+1 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (23 trials with phase data)• Click on a phase to view related trials

Phase 1
10 (43.5%)
Phase 3
8 (34.8%)
Phase 2
4 (17.4%)
Not Applicable
1 (4.3%)

A Study of SKB107 in Advanced Solid Tumors With Bone Metastases

Not Applicable
Not yet recruiting
Conditions
Metastatic Solid Tumors
Interventions
Drug: SKB107 for injection
First Posted Date
2025-07-25
Last Posted Date
2025-07-25
Lead Sponsor
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Target Recruit Count
90
Registration Number
NCT07087197
Locations
🇨🇳

Fudan University Shanghai Cancer Center, Shanghai, China

A Phase I Clinical Study of a Single Dose of KLA480

Phase 1
Recruiting
Conditions
Healthy Participants
Interventions
Drug: KLA480 injection
Drug: Placebo
First Posted Date
2025-06-22
Last Posted Date
2025-06-22
Lead Sponsor
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Target Recruit Count
20
Registration Number
NCT07030790
Locations
🇨🇳

Huashan Hospital affiliated to Fudan University, Shanghai, Shanghai, China

A Study of SKB518 in Patients With Lung Cancer

Phase 2
Not yet recruiting
Conditions
Lung Carcinoma
Interventions
Drug: SKB518 for injection
First Posted Date
2025-06-13
Last Posted Date
2025-06-13
Lead Sponsor
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Target Recruit Count
80
Registration Number
NCT07019675
Locations
🇨🇳

Cancer Hospital Chinese Academy of Medical Science, Beijing, China

SKB445 for Injection in Solid Tumors

Phase 1
Recruiting
Conditions
Advanced Solid Tumors
Interventions
Drug: SKB445 for injection
First Posted Date
2025-02-13
Last Posted Date
2025-03-17
Lead Sponsor
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Target Recruit Count
126
Registration Number
NCT06826040
Locations
🇨🇳

Cancer Hospital of Shandong First Medical University, Jinan, Shandong, China

A Study on the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of SKB500 in Subjects with Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Advanced Solid Tumors
Interventions
First Posted Date
2024-12-16
Last Posted Date
2024-12-19
Lead Sponsor
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Target Recruit Count
180
Registration Number
NCT06736327
Locations
🇨🇳

JILIN Cancer Hospital, Jilin, China

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.